Results 21 to 30 of about 4,732,777 (361)

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Frontiers in Immunology, 2022
BackgroundAn open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable ...
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu   +11 more
doaj   +1 more source

Management of inoperable endometrial cancer [PDF]

Obstetrics & Gynecology Science, 2022
Some endometrial cancer (EMC) patients are not good candidates for primary surgery. The three major types of treatment for inoperable EMC are radiation therapy, chemotherapy, or their combination as neoadjuvant treatment before surgery. Radiation therapy
Supakorn Pitakkarnkul, Saranya Chanpanitkitchot, Siriwan Tangjitgamol   +2 more
doaj   +1 more source

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.

The Journal of the National Comprehensive Cancer Network, 2022
The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously over the past several years. Currently, NAT is the preferred option for high-risk early triple-negative (TN) and HER2-positive (HER2+) breast cancers and is ...
Laura M. Spring, Yael Bar, S. Isakoff
semanticscholar   +1 more source

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer

Frontiers in Immunology, 2023
ObjectivesRecent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response.
Jie Shen, Linping Gu, Yuwen Qi, Yaxian Yao, Shun Lu, Zhiwei Chen   +5 more
doaj   +1 more source

Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2020
Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still controversial. We carried out the study to evaluate the efficacy and safety of
Yijiu Ren, Hai Tang, Jie Zhang, Yunlang She, Xiaoting Sun, Dong Xie, Chang Chen   +6 more
doaj   +1 more source

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma

npj Breast Cancer, 2021
Neoadjuvant therapy in breast cancer can downstage axillary lymph nodes and reduce extent of axillary surgery. As such, accurate determination of nodal status after neoadjuvant therapy and before surgery impacts surgical management. There are scarce data
Mary Kathryn Abel, Heather Greenwood, Tatiana Kelil, Ruby Guo, Case Brabham, Nola Hylton, Jasmine Wong, Michael Alvarado, Cheryl Ewing, Laura J. Esserman, Judy C. Boughey, Rita A. Mukhtar   +11 more
doaj   +1 more source

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Background: Significant survival benefit of adjuvant imatinib therapy has been observed in gastrointestinal stromal tumor (GIST). However, the impact of neoadjuvant imatinib on prognosis of GIST remains unclear.
Zhen Liu, Zimu Zhang, Juan Sun, Jie Li, Ziyang Zeng, Mingwei Ma, Xin Ye, Fan Feng, Weiming Kang   +8 more
doaj   +1 more source

Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keyst

Annals of Translational Medicine, 2022
Background Esophageal squamous cell carcinoma (ESCC) is one of the most refractory malignant tumors. Esophageal cancer (EC) is a malignant tumor with a high incidence worldwide, and over 50% of EC cases occur in China.
X. Shang, Gang Zhao, Fei Liang, Chen Zhang, Weihong Zhang, L. Liu, Runmei Li, X. Duan, Zhao Ma, J. Yue, Chuan-gui Chen, B. Meng, Xiubao Ren, Hongjing Jiang   +13 more
semanticscholar   +1 more source

Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma

Journal of the National Cancer Center, 2022
: Objective: This is a prospective, single-arm, phase Ib study to evaluate the safety and efficacy of camrelizumab combined with chemotherapy and apatinib as neoadjuvant therapy for locally advanced thoracic esophageal squamous cell carcinoma (ESCC ...
Zhen Wang, Xiankai Chen, Yong Li, Jianjun Qin, Yuan Fang, Zhaoyang Yang, Yan Fang, Dong Qu, Ruixiang Zhang, Qingfeng Zheng, Xiaozheng Kang, Liyan Xue, Jing Huang, Yin Li, Jie He   +14 more
doaj   +1 more source

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Frontiers in Oncology, 2021
BackgroundImmune checkpoint inhibitors (ICIs) have shown promising anti-tumor activity in multiple malignances including breast cancer. However, the responses can vary.
Yunhai Li, Lei Xing, Fan Li, Hong Liu, Lu Gan, Dejuan Yang, Mengxue Wang, Xuedong Yin, Hongyuan Li, Guosheng Ren, Guosheng Ren   +10 more
doaj   +1 more source